European regulators make recommendations drawing on lessons learnt from presence of nitrosamines in sartan medicines

Recommendations aim to clarify roles and responsibilities of companies involved in manufacture of medicines and to amend guidance on controlling impurities and good manufacturing practice.They also cover the management of impurities once detected & communication with stakeholders


European Medicines Agency